Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLE Study: Tamibarotene (AM80) plus pembrolizumab in late-line pancreatic cancer
jRCTs041230168Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamibarotene and pembrolizumab in pancreatic cancer (PC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Response rate. Started Jun 2024; status: active, not recruiting.
02
Drugs
tamibarotenepembrolizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041230168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230168.